The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.

The researchers found that between 1999 and 2022, there were 63,550,429 deaths in the United States, of which 0.06% had cold recorded as an underlying or contributing cause of death. Cold-related ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Health sector's share of the economy was similar in 2023 and 2022, but lower than in 2020 and 2021, during height of COVID-19 ...

(HealthDay News) — For adults with migraine, atogepant 60mg once daily was superior to placebo for efficacy and functional measures of treatment across 3 trials, according to research published online ...

The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.